XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

Media coverage

• Title	XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa
  Media name/outlet	Nasdaq
  Country/Territory	United States
  Date	23/10/19
  URL	https://www.nasdaq.com/press-release/xbiotech-announces-first-patient-enrolled-in-randomized-multi-center-clinical-study
  Persons	Alice Gottlieb